Xin Lang Cai Jing·2026-04-02 06:54Core Insights - The report from CMB International indicates that Kanglong Chemical (03759) is expected to achieve a revenue and adjusted net profit growth of 14.8% and 13.0% respectively for the full year of 2025, positioning at the higher end of previous guidance and earnings forecasts [1][3] - In Q4 2025, revenue and adjusted net profit are projected to grow by 15.9% and 18.0% respectively, showing acceleration compared to Q3 2025 [1][3] Segment Analysis - Laboratory Services and Small Molecule CDMO in Q4 2025 are expected to grow by 17.9% and 17.6% respectively, with new orders for the full year increasing by 12% and 13% year-on-year [1][3] - The gross margin for Small Molecule CDMO continues to improve quarterly, reaching 37.8%, with a commercial production agreement for oral GLP-1 formulations signed in Q1 2026, which is anticipated to be a significant growth driver from 2027 onwards [1][3] - The revenue for Large Molecule/CGT in Q4 2025 is projected to surge by 43%, benefiting from integrated project deliveries in Liverpool's gene therapy CDMO services, achieving a record annual revenue and effectively mitigating short-term profit margin impacts from the new capacity in Ningbo [1][3] - Clinical Services in Q4 2025 are expected to face revenue and gross margin pressures due to industry consolidation and price competition, although the number of service projects has increased compared to the end of H1 2025, reflecting the enhanced brand influence and competitiveness of Kanglong [1][3] Future Outlook - The company anticipates a revenue growth of 12-18% for 2026, accounting for a potential negative impact of approximately 3 percentage points from the appreciation of the Renminbi [1][3] - The gross margin for CDMO is expected to have room for improvement [1][3] Laboratory Services Performance - In Laboratory Services, the revenue from Biological Sciences is projected to grow nearly 20% year-on-year, outpacing Laboratory Chemistry at around 10%, contributing over 56% to the segment's revenue [2][4] - Within Biological Sciences, the revenue share from new molecular type service projects is rapidly increasing to around 15%, driven by efficient collaboration across technology platforms and the application of AI and automation technologies [2][4] CDMO Business Development - The CDMO business is rapidly enhancing its production and service capabilities for new molecular types, including the commissioning of early clinical production facilities for ADC conjugates and ongoing construction of mid-to-late stage clinical and commercial production capacities [2][4] - A larger-scale solid-phase synthesis facility for peptide APIs is expected to be completed in 2026, which will better accommodate downstream orders in high-growth areas such as weight loss and metabolism [2][4] Valuation and Rating - Based on the 2026 guidance, the profit forecast for 2026-27 has been raised by 1-2%, with a target price maintained at HKD 32.5 / RMB 47.3 using a discounted exit valuation method and a target exit P/E multiple of 21 times [2][4]